Vancomycin removal during low-flux and high-flux extended daily hemodialysis in critically ill septic patients

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Dec;156(4):342-7. doi: 10.5507/bp.2012.002. Epub 2012 Jan 30.

Abstract

Aims: To determine the extent of vancomycin removal and vancomycin pharmacokinetics in septic patients with AKI using daily hemodialysis with polysulphone high-flux and low-flux membrane.

Methods: Five patients received 6 h daily dialysis with low-flux polysulphone membrane, four patients with high-flux polysulphone membrane. Vancomycin was administered over the last hour of dialysis. The maintenance dose was adjusted based on pre-hemodialysis serum concentrations. Patients were followed up for two days.

Results: Median percentage of vancomycin removal by low-flux membrane dialysis was 17% (8-38%) and by high-flux membrane dialysis was 31% (13-43%). Vancomycin clearance was only moderately higher in high-flux membrane dialysis (median 3.01 L/h, range 2.34-3.5 L/h) compared to low-flux dialysis (median 2.48 L/h, range 0.53-5.68 L/h) in the first day of the study. About two-fold higher vancomycin clearance in high-flux dialysis (median 3.62 L/h, range 1.37-5.07 L/h) was observed on the second day of the study than low-flux dialysis (median 1.74 L/h, range 0.75-30.94 L/h).

Conclusions: Both high-flux and low-flux membrane dialysis remove considerable amounts of vancomycin in critically ill septic patients with AKI. Application of vancomycin after each dialysis was required to maintain therapeutic concentrations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / pharmacokinetics*
  • Humans
  • Male
  • Middle Aged
  • Renal Dialysis*
  • Sepsis / drug therapy*
  • Sepsis / metabolism
  • Vancomycin / pharmacokinetics*

Substances

  • Anti-Bacterial Agents
  • Vancomycin